# Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients

> **NCT05523739** · PHASE1 · COMPLETED · sponsor: **Zhejiang ACEA Pharmaceutical Co. Ltd.** · enrollment: 79 (actual)

## Conditions studied

- SARS-CoV-2 Infection

## Interventions

- **DRUG:** STI-1558

## Key facts

- **NCT ID:** NCT05523739
- **Lead sponsor:** Zhejiang ACEA Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-16
- **Primary completion:** 2022-12-21
- **Final completion:** 2023-03-29
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05523739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05523739, "Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05523739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*